Effects of short-term dexamethasone treatment on collagen synthesis and degradation markers in preterm infants with developing lung disease.
OBJECTIVE
To assess the effects of dexamethasone treatment on collagen turnover in preterm infants.


METHODS
The serum concentrations of the amino-terminal propeptide of type I and III procollagens (PINP and PIIINP), which reflect rates of type I and III collagen synthesis, respectively, and the carboxy-terminal telopeptide of type I procollagen (ICTP), which reflects the rate of type I collagen degradation, were monitored in 13 preterm infants receiving dexamethasone and 13 matched control infants without glucocorticoid treatment for a total period of 12 mo. Dexamethasone was started at a median age of 12 d and continued at tapering doses for a median total duration of 10 d. Blood samples were taken immediately after birth, at 7, 14 and 28 d of age and at 2, 3, 6, 9 and 12 mo. The same markers were also measured just before the initiation of dexamethasone and on days 1, 3, and 7 of treatment.


RESULTS
A striking decrease in all of the markers was already observed in every case on day 1 of dexamethasone, the suppression being greatest on day 3 and still considerable on day 7. The percentages from the pretreatment levels recorded on days 1, 3 and 7 were: for PINP 51, 26 and 45%; for PIIINP 63, 44% and 52%; and for ICTP 64, 41 and 51%. A rebound rise in PINP levels was seen in dexamethasone-treated infants, the levels exceeding those of the controls at 3 and 6 mo of age. A similar phenomenon was noted concerning PIIINP at 3 mo. The levels settled down at 9 and 12 mo.


CONCLUSIONS
Dexamethasone causes an immediate, inevitable, deep suppression of type I and III collagen synthesis and also type I collagen degradation. This should be taken into consideration, e.g. when assessing for the indications for steroid treatment in sick preterm infants and its dosing and duration.
Saarela
T
T
Department of Paediatrics, University of Oulu, Oulu, Finland. timo.saarela@oulu.fi
Risteli
J
J
Koivisto
M
M
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D002657:Child Development / Q000187:drug effects*; D003094:Collagen / Q000096:biosynthesis* / Q000187:drug effects*; D003907:Dexamethasone / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000139:chemically induced*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008137:Longitudinal Studies; D008171:Lung Diseases / Q000151:congenital* / Q000188:drug therapy*; D008297:Male; D011446:Prospective Studies; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D003907:Dexamethasone; D003094:Collagen